Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Axitinib (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 12 Jun 2017 Status changed from not yet recruiting to recruiting.
- 10 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jul 2017.